AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) (NCT07285694)
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- City of Hope — Duarte, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
- University of Iowa and Holden Comprehensive Cancer Center — Iowa City, Iowa
- The University of Kansas Cancer Center — Fairway, Kansas
- University of Minnesota — Minneapolis, Minnesota
- Perlmutter Cancer Center - NYU Langone Health — New York, New York
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (650) 446-4874
Email: clinicaltrials@arsenalbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC — Casa Grande, Arizona
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Tucson, Arizona
Explore by condition: All Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.